MeiraGTx Holdings plc: Business Overview, Financials & Competitive Analysis
MeiraGTx Holdings plc scores 7/10 on the AskCyborg Cyborg Score (Strong). Clinical-stage gene therapy company with validated manufacturing, strong partner validation, and multiple late-stage programs addressing high-unmet-need indications. MeiraGTx receives "Strong Buy" consensus from analysts with a 12-month price target of $25.67, representing 197% upside potential. The company has multiple late-stage programs and significant partnership validation, though faces typical clinical-stage.
What is MeiraGTx Holdings plc's industry? MeiraGTx Holdings plc (meiragtx.com) operates in Biotechnology - Gene Therapy. AskCyborg classifies MeiraGTx Holdings plc under Biotechnology - Gene Therapy in its company registry.
MeiraGTx is a vertically integrated, clinical-stage genetic medicines company developing AAV gene therapies for ocular diseases, Parkinson's disease, and radiation-induced xerostomia using local delivery of small dose...
Cyborg Score thesis
Clinical-stage gene therapy company with validated manufacturing, strong partner validation, and multiple late-stage programs...
Read the full analyst-debate transcript →Get the Latest MeiraGTx Holdings plc Report
Up-to-date AI-powered research, analyst debate audio & saved-company playlists
Get Current Report FreeMeiraGTx Holdings plc Overview
Pro stress-test →MeiraGTx is a vertically integrated, clinical-stage genetic medicines company developing AAV gene therapies for ocular diseases, Parkinson's disease, and radiation-induced xerostomia using local delivery of small doses. The company addresses significant unmet needs across inherited retinal diseases, neurodegenerative conditions, and salivary gland dysfunction.
Strategic Profile
Pro stress-test →MeiraGTx's competitive advantage lies in its end-to-end in-house manufacturing with 5 facilities globally, including two licensed for GMP viral vector production. In 2025, the company announced a strategic collaboration with Hologen including a $200 million cash upfront payment and formation of a joint venture with $230 million in committed capital.
Competitive Landscape
Pro stress-test →MeiraGTx collaborates with Johnson & Johnson Innovative Medicine on inherited retinal disease therapies and Hologen Limited on CNS programs. The company competes in the gene therapy space against other AAV developers but differentiates through vertically integrated manufacturing and proprietary viral vector optimization technology.
Industry Context
MeiraGTx Holdings plc operates in Biotechnology - Gene Therapy.
Key facts
Founded: 2015 · Headquarters: New York, United States · Revenue: $33.3M (2024) · Market cap: ~$550M